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Purpose
Localised scleroderma (LS) and juvenile systemic sclerosis
(jSSc) are very rare paediatric diseases managed by paedia-
tric rheumatologists and dermatologists[1]. Optimal treat-
ment is controversial in the absence of clinical trials, but
most paediatric rheumatologists advocate systemic immu-
nosuppression to avoid progressive deformity, functional
disability and disfigurement[2]. We aimed to describe
pathways through which children and young people
receive a diagnosis of LS or jSSc, and to document these
pathways from the time the first symptom was noticed by
the patient or their family, through to the time when a
diagnosis of LS or jSSc was first considered. We also
aimed to document the health care professionals involved
in these pathways to diagnosis.
Methods
We performed a retrospective case note audit of existing
patients under paediatric rheumatology care who have
presented between Jan 2005 – Jan 2010. Data was col-
lected using a piloted proforma. Each participating centre
identified children and young people who presented to
their services during Jan 2005 – Jan 2010. All data col-
lected was pseudo-anonymised and collected in accor-
dance with Caldicott guidelines. As this was an audit of
access to care no ethical approval was required. No
patient or family contact was necessary at any time dur-
ing this project.
Results
Eight centres provided data on 89 cases: 62 female, 26
male; 73 LS, 16 jSSc. Symptoms were first noticed at a
mean age of 6.8 years (1month–15 years) for LS and 8.5
years (9 months – 15 years) for jSSc. Mean total time from
first symptom to seeing a paediatric rheumatologist was
24.2 (1-103) months (LS) and 13.7 (0-50) months (jSSc).
Mean time from first symptom to seeing first health care
professional (HCP) was 8.0 (0-72) months (LS) and 8.8 (0-
50) months (jSSc). Mean time from seeing first HCP to
seeing a paediatric rheumatologist was 15.5 (0-103)
months (LS) and 2.9 (0-10) months (jSSc). First health
care professional (HCP) seen was usually (74%) a General
Practitioner (GP). Referring HCP to paediatric rheumatol-
ogy was usually a dermatologist (56%) for LS, and varied
for jSSc. Mean time from first symptom to diagnosis was
21.3 (1-191) months (LS) and 15.9 (1-50) months (jSSc).
The median number of HCPs seen prior to referral to a
paediatric rheumatologist was 2 (1-5).
Conclusion
There is a prolonged interval from first symptom to
assessment by a paediatric rheumatologist and diagnosis.
GPs are usually the initial HCP to assess; dermatologists
usually the HCP referring to paediatric rheumatology
services. The prolonged interval to diagnosis may
adversely affect outcome and there is need to raise
awareness of this rare diagnosis and facilitate earlier
recognition.
5Nottingham Children’s Hospital, Nottingham, Nottinghamshire, UK
Full list of author information is available at the end of the article
Hawley et al. Pediatric Rheumatology 2012, 10(Suppl 1):A67
http://www.ped-rheum.com/content/10/S1/A67
© 2012 Hawley et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Disclosure
Daniel P. Hawley: None; Eileen M. Baildam: None;
Tania S. Amin: None; Mary K. Cruikshank: None; Joyce
E. Davidson: None; Jennifer Dixon: None; Neil S. Mar-
tin: None; Victoria Ohlsson: None; Clarissa A. Pilking-
ton: None; Satyapal Rangaraj: None; Philip Riley: None;
Chitra Sundaramoorthy: None; Jo Walsh: None; Helen
E. Foster: None.
Author details
1Derriford Hospital, Plymouth, Devon, UK. 2Great Ormond Street Hospital,
London, UK. 3Newcastle Hospital’s NHS Trust, Newcastle-upon-Tyne,
Tyneside, UK. 4Newcastle Hospitals NHS Trust, Newcastle-upon-Tyne,
Tyneside, UK. 5Nottingham Children’s Hospital, Nottingham, Nottinghamshire,
UK. 6Royal Hospital for Sick Children Edinburgh, Edinburgh, Lothian, UK.
7Royal Hospital for Sick Children Glasgow, Glasgow, Lanarkshire, UK. 8Royal
Hospital for Sick Children Glasgow and Edinburgh, Edinburgh, Lothian, UK.
9Royal Liverpool Children’s Hospital, Liverpool, Mersyside, UK. 10Royal
Manchester Children’s Hospital, Manchester, Lancashire, UK.
Published: 13 July 2012
References
1. Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM: Incidence of
childhood linear scleroderma and systemic sclerosis in the UK and
Ireland. Arthritis Care Res (Hoboken) 2010, 62(2):213-8.
2. Li SC, Feldman BM, Higgins GC, et al: Treatment of pediatric localized
scleroderma: results of a survey of North American pediatric
rheumatologists. J Rheumatol 2010, 37(1):175-81, Epub 2009 Nov 16.
doi:10.1186/1546-0096-10-S1-A67
Cite this article as: Hawley et al.: Retrospective audit of access to care
for children and young people diagnosed with localised scleroderma or
juvenile systemic sclerosis in the United Kingdom. Pediatric
Rheumatology 2012 10(Suppl 1):A67.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hawley et al. Pediatric Rheumatology 2012, 10(Suppl 1):A67
http://www.ped-rheum.com/content/10/S1/A67
Page 2 of 2
